The peripheral vascular treatment market encompasses the medical sector focused on diagnosing, managing, and treating diseases affecting the blood vessels outside the heart and brain, primarily peripheral artery disease (PAD) and venous conditions. It includes endovascular devices—such as stents, angioplasty balloons, drug-coated balloons, and atherectomy systems—as well as pharmacological therapies, surgical interventions, and diagnostic imaging technologies designed to restore blood flow and prevent vascular complications across hospitals, ambulatory surgical centers, and outpatient facilities.
The global peripheral vascular devices market was valued at USD 9.55 billion in 2025 and USD 10.02 billion in 2026, and it is projected to reach USD 13.22 billion by 2031, growing at a compound annual growth rate (CAGR) of 5.7%.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=790
The peripheral vascular treatment market is primarily driven by the surging global prevalence of cardiovascular diseases, peripheral artery disease (PAD), and lifestyle-related conditions like diabetes and hypertension, alongside an aging global population and a growing preference for minimally invasive endovascular procedures. However, market growth is heavily restrained by the high cost of advanced vascular devices, stringent regulatory approval processes, reimbursement disparities, and competition from non-invasive pharmacological therapies. Lucrative opportunities exist in the rapid expansion of healthcare infrastructure in high-growth emerging markets across the Asia-Pacific and Latin America, alongside continuous technological innovations in next-generation drug-coated balloons, bioresorbable scaffolds, and AI-assisted imaging guidance. Despite these favorable prospects, the market faces key challenges including the risk of severe procedural complications like thrombosis or vessel restenosis, device recall risks, intense institutional pricing pressures, and a global shortage of specialized vascular care professionals.
Target customers in the peripheral vascular treatment market primarily consist of institutional healthcare providers—such as public and private hospitals, specialized vascular clinics, ambulatory surgical centers (ASCs), and outpatient catheterization labs—alongside endovascular specialists, interventional cardiologists, and vascular surgeons who treat patients suffering from peripheral artery disease, thrombosis, and related vascular conditions. Healthcare providers demand highly effective, clinically validated devices—including drug-eluting stents, drug-coated balloons, atherectomy systems, and specialized catheters—that minimize procedural complications, ensure long-term vessel patency, and reduce hospital readmission rates. They prefer minimally invasive, precise endovascular tools that shorten recovery times, lower procedural trauma, and integrate seamlessly with modern imaging infrastructure. Purchasing behaviors among institutional buyers are heavily driven by stringent regulatory approvals, multi-year procurement contracts, clinical trial evidence, and established reimbursement policies, alongside a growing sensitivity toward total cost of ownership as procedures shift toward cost-effective outpatient and ASC settings.
Market entry, expansion, and profitability in the peripheral vascular treatment market are heavily driven by rigorous regulatory requirements, rapid technological advancements, and persistent economic pressures. Regulatory bodies, such as the U.S. FDA, enforce stringent approval pathways, clinical trial mandates, and post-market surveillance that ensure safety but increase compliance costs, delay product deployment, and present significant risks surrounding device recalls and quality control failures. Technologically, the market is being disrupted by advanced drug-eluting stents, bioresorbable scaffolds, intravascular imaging (such as OCT and IVUS), and AI-assisted workflow tools, requiring constant R&D investment for companies to maintain market relevance and procedural precision. Economically, while high chronic disease prevalence, an aging global population, and shifting care to ambulatory surgical centers propel long-term demand, market expansion is constrained by high initial device and procedural costs, complex reimbursement frameworks, and pricing pressures from institutional buyers, particularly within developing regions.
The peripheral vascular treatment market is being dynamically reshaped by a rapid clinical pivot toward minimally invasive endovascular interventions, rising adoption of advanced plaque-modification technologies, and the expansion of outpatient care settings. Key emerging trends include the widespread deployment of drug-eluting stents (DES), drug-coated balloons (DCBs), and next-generation atherectomy devices designed to cross complex calcified lesions while preserving long-term vessel patency. Additionally, procedural volume is increasingly shifting away from traditional hospital inpatient departments toward ambulatory surgical centers (ASCs) and office-based laboratories (OBLs), driven by healthcare cost-containment pressures, favorable reimbursement codings, and faster patient recovery times. These trends are evolving rapidly, supported by a projected compound annual growth rate of roughly 5.7% to 7.5% over the coming decade, further accelerated by the surging global prevalence of peripheral artery disease, diabetes, and an aging population.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=790
Technological innovations disrupting the peripheral vascular treatment market are centered on minimally invasive vessel restoration, advanced local drug delivery, and vessel preparation. Key advancements gaining significant traction include drug-coated balloons (DCBs) and drug-eluting stents (DES)—such as bioresorbable scaffolds—that deliver anti-proliferative therapeutics directly to vascular walls without leaving permanent structures behind. The market is also seeing rapid adoption of novel vessel preparation technologies, most notably intravascular lithotripsy (IVL) platforms and specialized atherectomy systems designed to modify severely calcified and complex lesions. Furthermore, the integration of smart material actuators, steerable microcatheters, bioengineered antiproliferative coatings, and real-time image-guided navigation is enhancing procedural precision, reducing restenosis rates, and accelerating the shift toward outpatient endovascular care.
In the peripheral vascular treatment market, short-term hype is primarily characterized by unvalidated early-stage gene therapy applications, temporary enthusiasm surrounding experimental non-stent delivery gadgets, and initial over-projection of unproven bioresorbable stent iterations before establishing long-term clinical patency. Conversely, long-term structural shifts are firmly anchored in the rapid adoption of drug-eluting technologies such as drug-coated balloons (DCBs) and drug-eluting stents (DES), the integration of AI-augmented intravascular imaging and real-time guidance tools into cath lab workflows, and an accelerating focus on specialized vessel preparation tools designed for severe, below-the-knee arterial calcification in expanding diabetic and critical limb-threatening ischemia (CLTI) patient populations.
